| abstract |
The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. n The present invention relates to a compound represented by the general formula (I):n n(wherein A represents;n nand R 1 , R 2 , R 3 and R 1 each a hydrogen atom or a substituent; nR 5 is a substituent; X - is an anion;the symbol:n ndenotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor. |